Doman, David B

Patel, Amar

Tamboli, Cyrus P

English

PubMed

Tamboli, CP

Doman, DB

Patel, A

George Washington University: Health Sciences Research Commons (HSRC)

Current and future role of biomarkers in Crohn\u27s disease risk assessment and treatment

A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease.

A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease.

A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn’s disease.

A novel algorithm-based approach using clinical parameters, genetic and serological markers to effectively predict aggressive disease behavior in patients with Crohn’s disease [abstract 207]. Presented at Digestive Disease Week;

A simple classification of Crohn’s disease: report of the Working Party for the World Congresses of Gastroenterology,

An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn’s disease. Aliment Pharmacol Ther.

Anti-flagellin (CBir1) phenotypic and genetic Crohn’s disease associations. Inflamm Bowel Dis.

Anti-neutrophil cytoplasmic antibodies in type 1 and 2 autoimmune hepatitis.

Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease.

Anti-Saccharomyces cerevisiae and perinuclear anti-neutrophil cytoplasmic antibodies in coeliac disease before and after gluten-free diet. Aliment Pharmacol Ther.

Anti-Saccharomyces cerevisiae antibodies (ASCA) and autoimmune liver diseases. Clin Exp Immunol.

Anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn’s disease are associated with disease severity but not NOD2/CARD15 mutations. Clin Exp Immunol.

Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families. Inflamm Bowel Dis.

Anti-Saccharomyces cerevisiae antibodies are frequent in type 1 diabetes. Endocr Pathol.

Anti-Saccharomyces cerevisiae antibodies in twins with inflammatory bowel disease.

Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn’s disease.

Anti-Saccharomyces cerevisiae IgA antibodies are raised in ankylosing spondylitis and undifferentiated spondyloarthropathy. Ann Rheum Dis.

Anti-Saccharomyces cerevisiae mannan antibodies in familial Crohn’s disease.

Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn’s disease.

Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn’s disease.

Antibodies to Saccharomyces cerevisiae in Crohn’s disease: higher titers are associated with a greater frequency of mutant NOD2/CARD15 alleles and with a higher probability of complicated disease. Inflamm Bowel Dis.

Antibodies to tissue transglutaminase and Saccharomyces cerevisiae in ankylosing spondylitis and psoriatic arthritis.

Antibody to Saccharomyces cerevisiae (bakers’ yeast) in Crohn’s disease.

Antineutrophil and pancreatic autoantibodies in first-degree relatives of patients with inflammatory bowel disease.

Antineutrophil cytoplasmic antibodies in relatives of patients with inflammatory bowel disease.

AntiSaccharomyces cerevisiae antibody does not differentiate between Crohn’s disease and intestinal tuberculosis. Dig Dis Sci.

Association of antibody responses to microbial antigens and complications of small bowel Crohn’s disease.

Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: results of a pilot study. Mayo Clin

Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease.

Association of perinuclear antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies with Vienna classification subtypes of Crohn’s disease. Inflamm Bowel Dis.

Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn’s disease. Clin Gastroenterol Hepatol.

Autoantibodies in nonautoimmune individuals during infections.

Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med.

Bacterial flagellin is a dominant antigen in Crohn disease.

Both preoperative perinuclear antineutrophil cytoplasmic antibody and anti-CBir1 expression in ulcerative colitis patients influence pouchitis development after ileal pouch-anal anastomosis. Clin Gastroenterol Hepatol.

C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study.

Candida albicans colonization and ASCA in familial Crohn’s disease.

Candida albicans is an immunogen for anti-Saccharomyces cerevisiae antibody markers of Crohn’s disease.

CARD15/NOD2 gene variants are associated with familially occurring and complicated forms of Crohn’s disease.

CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease.

Certolizumab pegol for the treatment of Crohn’s disease.

Clinical course and costs of care for Crohn’s disease: Markov model analysis of a populationbased cohort.

Clinical course in Crohn’s disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol.

Combination of innate and adaptive immune alterations increased the likelihood of fibrostenosis in Crohn’s disease. Inflamm Bowel Dis.

Crohn’s disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn’s disease activity index and endoscopic findings. Inflamm Bowel Dis.

Defining complex contributions of NOD2/CARD15 gene mutations, age at onset, and tobacco use on Crohn’s disease phenotypes. Inflamm Bowel Dis.

Determination of serologic and genetic markers aid in the determination of the clinical course and severity of patients with IBD. Inflamm Bowel Dis.

Diagnosis of gastrointestinal tuberculosis. Trop Gastroenterol.

Diagnostic precision of anti-Saccharomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease.

Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease.

Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm Bowel Dis.

Disease activity courses in a regional cohort of Crohn’s disease patients.

Disease behavior in adult patients: are there predictors for stricture or fistula formation? Dig Dis.

Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial.

Early Crohn’s disease shows high levels of remission to therapy with adalimumab: sub-analysis

Economic implications of biological therapies for Crohn’s disease: review of infliximab.

Effects of cigarette smoking on the long-term course of Crohn’s disease.

Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn’s disease. Inflamm Bowel Dis.

Familial aggregation and antimicrobial response dose-dependently affect the risk for Crohn’s disease. Inflamm Bowel Dis.

Familial expression of antiEscherichia coli outer membrane porin C in relatives of patients with Crohn’s disease.

Fecal calprotectin levels and serological responses to microbial antigens among children and adolescents with inflammatory bowel disease. Inflamm Bowel Dis.

Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti- TNF-alpha therapy for Crohn’s disease. Inflamm Bowel Dis.

Frequency of ASCA seropositivity in children with cystic fibrosis.

Genetic variants of the mannanbinding lectin are associated with immune reactivity to mannans in Crohn’s disease.

Genome wide association (GWA) predictors of anti-TNFalpha therapeutic responsiveness in pediatric inflammatory bowel disease. Inflamm Bowel Dis.

Genome-wide metaanalysis increases to 71 the number of confirmed Crohn’s disease susceptibility loci.

Guidelines for the management of inflammatory bowel disease in adults.

High level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouch-anal anastomosis.

High-level serum antibodies to bacterial antigens are associated with antibiotic-induced clinical remission in Crohn’s disease: a pilot study. Dig Dis Sci.

Higher remission and maintenance of response rates with subcutaneous monthly certolizumab pegol in patients with recentonset Crohn’s disease: data from PRECiSE 2 [abstract 1109]. Am

IBD serological panels: facts and perspectives. Inflamm Bowel Dis.

Identification of a novel bacterial sequence associated with Crohn’s disease.

Impact of the increasing use of immunosuppressants in Crohn’s disease on the need for intestinal surgery.

Increased immune reactivity predicts aggressive complicating Crohn’s disease in children. Clin Gastroenterol Hepatol.

Infliximab drug and infusion costs among patients with Crohn’s disease in a commercially-insured setting.

Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease.

Is CBir1 a predictor of pediatric inflammatory bowel disease? [abstract 2]. J Pediatr Gastroenterol Nutr.

Linkage of Crohn’s diseaserelated serological phenotypes: NFKB1 haplotypes are associated with anti-CBir1 and ASCA, and show reduced NF-kappaB activation.

Long-term evolution of disease behavior of Crohn’s disease. Inflamm Bowel Dis.

Mannan-binding lectin deficiency results in unusual antibody production and excessive experimental colitis in response to mannose-expressing mild gut pathogens.

Marker antibody expression stratifies Crohn’s disease into immunologically homogeneous subgroups with distinct clinical characteristics.

Molecular prediction of disease risk and severity in a large Dutch Crohn’s disease cohort.

Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn’s disease.

National Cooperative Crohn’s Disease Study: results of drug treatment.

Natural history of pediatric Crohn’s disease: a population-based cohort study.

Natural history of recurrent Crohn’s disease at the ileocolonic anastomosis after curative surgery.

New serological markers in inflammatory bowel disease are associated with complicated disease behaviour.

NOD2 variants and antibody response to microbial antigens in Crohn’s disease patients and their unaffected relatives.

Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.

Optimising the diagnostic value of anti-Saccharomyces cerevisiae-antibodies (ASCA) in Crohn’s disease.

Penetrance of NOD2/CARD15 genetic variants in the general population.

Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn’s disease define a clinical subgroup.

Phenotypic associations of Crohn’s disease with antibodies to flagellins A4-Fla2 and Fla-X, ASCA, p-ANCA, PAB, and NOD2 mutations in a Swiss Cohort. Inflamm Bowel Dis.

Positioning biologic agents in the treatment of Crohn’s disease. Inflamm Bowel Dis.

Predictive model for the outcome of infliximab therapy in Crohn’s disease based on apoptotic pharmacogenetic index and clinical predictors. Inflamm Bowel Dis.

Predictive value of serologic markers in a population-based Norwegian cohort with inflammatory bowel disease. Inflamm Bowel Dis.

Predictors of Crohn’s disease.

Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis.

Prevalence and clinical significance of auto-antibodies in adults with cystic fibrosis.

Review article: altering the natural history of Crohn’s disease – evidence for and against current therapies. Aliment Pharmacol Ther.

http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3132855

Current and future role of biomarkers in Crohn’s disease risk assessment and treatment

Current and future role of biomarkers in Crohn’s disease risk assessment and treatment

Abstract

Similar works

Full text

Available Versions

George Washington University: Health Sciences Research Commons (HSRC)